Reconnecting

The current page stays visible while onset.to reconnects in the background.

Preclinical mouse study finds psilocybin may prevent chemotherapy-induced nerve damage by preserving mitochondrial transport

Open original

Preclinical research suggests that preventive psilocybin may protect sensory nerves from chemotherapy-induced peripheral neuropathy. In mice receiving cisplatin or paclitaxel, two doses given before chemotherapy prevented pain-related hypersensitivity and cold sensitivity across six treatment cycles and an eight-month follow-up. The compound preserved mitochondrial movement along long sensory axons by activating serotonin 2A receptor signaling, helping nerve endings maintain the energy needed to withstand chemotherapy. Psilocybin did not reduce tumor shrinkage or alter systemic immune markers, and a nonhallucinogenic compound targeting the same receptor produced similar protection. Human sensory neurons and peripheral nerve tissue also showed improved mitochondrial trafficking in laboratory tests. However, the evidence remains preclinical: psilocybin did not reverse damage once neuropathy was established, and questions about dosing, timing, safety, interactions, psychiatric screening, and clinical benefit remain unresolved. A planned Phase 2 NeuroGuard trial will evaluate the approach in patients receiving chemotherapy.